Your browser doesn't support javascript.
loading
Effects of Hormone Therapy on Oxidative Stress in Postmenopausal Women with Metabolic Syndrome.
Sánchez-Rodríguez, Martha A; Zacarías-Flores, Mariano; Castrejón-Delgado, Lizett; Ruiz-Rodríguez, Ana Karen; Mendoza-Núñez, Víctor Manuel.
Afiliação
  • Sánchez-Rodríguez MA; Unidad de Investigación en Gerontología, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Guelatao No. 66, Col. Ejército de Oriente, Ciudad de México, México CP 09230, Mexico. masanrod@yahoo.com.mx.
  • Zacarías-Flores M; División de Ginecología y Obstetricia, Hospital General Dr. Gustavo Baz Prada, Instituto de Salud del Estado de México, Av. Bordo de Xochiaca esq. Adolfo López Mateos S/N, Col. Tamaulipas, Nezahualcóyotl, Estado de México, México CP 57300, Mexico. mzacariasf@yahoo.com.
  • Castrejón-Delgado L; Unidad de Investigación en Gerontología, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Guelatao No. 66, Col. Ejército de Oriente, Ciudad de México, México CP 09230, Mexico. lizettcastrejon@hotmail.com.
  • Ruiz-Rodríguez AK; Unidad de Investigación en Gerontología, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Guelatao No. 66, Col. Ejército de Oriente, Ciudad de México, México CP 09230, Mexico. hikary90@hotmail.com.
  • Mendoza-Núñez VM; Unidad de Investigación en Gerontología, Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Guelatao No. 66, Col. Ejército de Oriente, Ciudad de México, México CP 09230, Mexico. mendovic@unam.mx.
Int J Mol Sci ; 17(9)2016 Aug 24.
Article em En | MEDLINE | ID: mdl-27563883
The aim of this study was to determine the effect of oral hormone therapy (HT) on oxidative stress (OS) in postmenopausal women with metabolic syndrome (MetS). A randomized, double blind, placebo-controlled trial was carried out. We formed four groups of 25 women each; healthy (HW) and MetS women (MSW) were assigned to HT (1 mg/day of estradiol valerate plus 5 mg/10 day of medroxiprogesterone) or placebo. We measured plasma lipoperoxides, erythrocyte superoxide dismutase and glutathione peroxidase, total plasma antioxidant status and uric acid, as OS markers. Alternative cut-off values of each parameter were defined and a stress score (SS) ranging from 0 to 7 was used as total OS. MetS was defined according to National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII) criteria. Participants were seen at baseline, 3 and 6 months. After 6 months, MetS decreased in MSW-HT (48%), their triglycerides and high-density lipoprotein cholesterol (HDL-c) improved; in the other groups no difference was found. SS in MSW-HT decreased (3.8 ± 0.3 to 1.7 ± 0.3, p < 0.05) and OS was also reduced (44%), this effect was evident since 3 mo. HW-HT with high OS also decreased (40%). In placebo groups there was no change. Our findings suggest that HT improve lipids and OS associated to MetS in postmenopausal women.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estresse Oxidativo / Síndrome Metabólica / Estradiol / Medroxiprogesterona Tipo de estudo: Clinical_trials Limite: Female / Humans / Middle aged Idioma: En Revista: Int J Mol Sci Ano de publicação: 2016 Tipo de documento: Article País de afiliação: México País de publicação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estresse Oxidativo / Síndrome Metabólica / Estradiol / Medroxiprogesterona Tipo de estudo: Clinical_trials Limite: Female / Humans / Middle aged Idioma: En Revista: Int J Mol Sci Ano de publicação: 2016 Tipo de documento: Article País de afiliação: México País de publicação: Suíça